Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by LannyMcdonaldon Jan 12, 2018 12:37pm
154 Views
Post# 27342917

Screening Sites in your local pharmacy! Brilliant !

Screening Sites in your local pharmacy! Brilliant !

Screening sites in your local pharmacy's, brilliant . We talked on this board last year about doing this. This will definitely help to screen the masses. The diabetic epidemic needs to be brought under control. Diagnos and Novo Nordisk are still breaking new ground in terms of screening site locations. This is just the tip of the iceberg.What works in Mexico will work in other countries also. Teaming up with Novo Nordisk was a brilliant move too!
 

Novo Nordisk - We needed an accurate technology platform to match our high quality of standards, and Diagnos filled the requirements 

Novo Nordisk

The company’s overall strategy is to generate profitable growth in three therapeutic areas: diabetes, growth hormone deficiencies and haemophilia. All of this rests on a strong foundation of shared values: The 
Novo Nordisk Way, a value-based management system. With the increasing severity of diabetes in MexicoNovo Nordisk is committed more than ever to combating the disease, and will continue to work hard to be the leader in the Mexican market.

Novo Nordisk is a world leader in the treatment of diabetes. It offers a complete range of products in the pharmaceutical industry for diabetes, including the most advanced insulin delivery systems that are preferred by patients and health professionals all over the world.

The Novo Nordisk Way

The Novo Nordisk Way is a set of guiding principles which underpins every decision we make.

It describes who we are, how we work and what we want to achieve, and sets a clear direction for our company and our employees. 

Ultimately, it’s a promise we make to each other - and to the millions of patients all over the world who rely on our products to lead full and healthy lives.

 

 

Novo Nordisk Way is our way

In 1923, our Danish founders began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, skills and commitment to drive change to defeat diabetes and other serious chronic diseases.

  • We aim to lead in all disease areas in which we are active.
  • Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.
  • Growing our business and delivering competitive financial results is what allows us to help patients live better lives, offer an attractive return to our shareholders and contribute to our communities.
  • Our business philosophy is one of balancing financial, social and environmental considerations - we call it 'The Triple Bottom Line'.
  • We are open and honest, ambitious and accountable, and treat everyone with respect.
  • We offer opportunities for our people to realise their potential.
  • We never compromise on quality and business ethics.

Every day, we must make difficult choices, always keeping in mind, what is best for patients, our employees and our shareholders in the long run.

It's our way. It's the Novo Nordisk Way.


Now this is someone that I would want on my team !!!









Bullboard Posts